English
Français
Español
Deutsch
Italiano
Português
Nederlands
Polski
Română
Svenska
Dansk
Suomi
Čeština
Ελληνικά
Magyar
SlovenčinaData temporarily unavailable
Unable to load analysis for « - » for now. Try again in a few moments.
Investlytic score: 1/5 criteria met. Data as of 01/11/2026.
- ❌ Price trend failed
- ❌ Growth failed
- ✅ Debt passed
- ❌ P/E failed
- ❌ Correction failed
Price trend
Overall trend (8 years): insufficient progression (less than x1.5).
Price change 2024 → 2025: -78.37%
Price change 2025 → 2026: -84.23%
Price change 2026 (year to date): -83.73%
Financial growth
Revenue CAGR (8 years): N/A
Earnings CAGR (8 years): N/A
Growth status: insufficient data or negative trend.
Debt
Debt-to-equity ratio: 0.18
Debt/equity < 0.5 (maximum threshold).
P/E (Price/Earnings)
P/E ratio: -7.97
P/E > 25.0 (maximum threshold).
Correction (6 months)
Current correction: 88.13% from the high over 6 months.
Excessive correction (> 20.0%).
Criteria of the Investlytic model
- / 5Free with the Investlytic logo. Paste this line into your page: options.
<script src="https://investlytic.co/encart.js" data-symbole="ATYR" data-lang="en"></script>Price trend
Price & trend
Interactive chart →💰 Dividend
Dividend ranking →⚖️ Comparison with the market
All stocks →| Stock | P/E | Dette/FP | Revenue growth | Rating |
|---|---|---|---|---|
| aTyr Pharma, Inc. | – | 0.18 | – | 🔒 |
| Aelis Farma S.A. | – | 1.49 | +49.1 % | – |
| SpineGuard S.A. | – | 0.27 | +1.6 % | – |
| Biosynex S.A. | – | 1.90 | +35.4 % | – |
| Implanet S.A. | – | 14.66 | +5.0 % | – |
Data from the Investlytic screener. The rating of the stock being viewed is reserved for members.
Detailed analysis · Price trend
-
Revenues & profits
Revenue and net income
Financial indicators
Annual financial statements
| Fiscal year | Revenue | Net income | Net margin | EPS | Revenue growth |
|---|
Key reported figures
Revenue, net income and net margin reported by aTyr Pharma, Inc. over the latest fiscal years.
| Fiscal year | Revenue | Net income | Net margin | Revenue growth |
|---|---|---|---|---|
| 2019 | 422,000 | -23.6 m | -5,593.1 % | n/a |
| 2020 | 10.5 m | -16.2 m | -155.2 % | +2,377.5 % |
| 2022 | 10.4 m | -45.3 m | -436.5 % | -0.7 % |
| 2023 | 353,000 | -50.4 m | -14,274.5 % | -96.6 % |
| 2024 | 235,000 | -64.0 m | -27,243.8 % | -33.4 % |
| 2025 | 190,000 | -74.1 m | -39,009.5 % | -19.1 % |
Amounts converted to USD. Source: published annual accounts, collected on 06/11/2026.
Accounts and financial health
Balance sheet and cash flow published by aTyr Pharma, Inc. over the last fiscal years, strength scores and valuation by discounted cash flow (DCF).
| Fiscal year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Cash and investments | 108 m | 66.1 m | 98.2 m | 72.1 m | 78.7 m |
| Total Debt | 1.4 m | 11.5 m | 15.1 m | 13.3 m | 12.0 m |
| Net Debt | -958,000 | 1.6 m | -7.4 m | 2.2 m | 1.3 m |
| Equity | 109 m | 71.5 m | 90.7 m | 70.0 m | 67.5 m |
| Total assets | 116 m | 95.8 m | 121 m | 96.8 m | 94.2 m |
| Operating cash flow | -33.1 m | -41.9 m | -33.2 m | -69.1 m | -62.0 m |
| Investments (capex) | 192,000 | 1.6 m | 4.2 m | 65,000 | 77,000 |
| Free cash-flow | -33.3 m | -43.5 m | -37.4 m | -69.2 m | -62.1 m |
| Share buybacks | 0 | 0 | 0 | 0 | 0 |
| Dividends paid | 0 | 0 | 0 | 0 | 0 |
Amounts in USD, currency of the published accounts.
Trailing 12-month ratios
Altman Z: default risk estimated from the balance sheet and earnings. Piotroski: 9 tests on profitability, debt and efficiency. DCF: estimated value from discounted future cash flows, a model and not a forecast. Source: annual accounts published by the company, data as of 09/11/2026.
Valuation and competitors
aTyr Pharma, Inc. compared with its sector on the same exchange and with its main competitors.
Direct competitors
| Company | Market cap (USD) | P/E | Net margin |
|---|---|---|---|
| aTyr Pharma, Inc. | 12.1 m | n/a | -39,009.5 % |
| ALX Oncology Holdings Inc. ALXO | 169 m | n/a | 0.0 % |
| CAMP4 Therapeutics Corporation CAMP | 249 m | n/a | -2,298.5 % |
| Quince Therapeutics, Inc. QNCX | 8.8 m | n/a | 0.0 % |
| Metagenomi, Inc. Common Stock MGX | 29.5 m | n/a | -348.5 % |
| Unicycive Therapeutics, Inc. UNCY | 102 m | n/a | 0.0 % |
| Relmada Therapeutics, Inc. RLMD | 382 m | n/a | 0.0 % |
| Acrivon Therapeutics, Inc. Common Stock ACRV | 71.1 m | n/a | 0.0 % |
| MindWalk Holdings Corp. HYFT | 53.2 m | n/a | -123.3 % |
| Sector median (Nasdaq) | 20.5 |
Trailing 12-month P/E. Sector: median of companies in the same sector listed on the same exchange, collected on . Competitors: comparable companies named by the data provider.
Analyst consensus and forecasts
What the financial analysts covering aTyr Pharma, Inc. publish: ratings, price targets and earnings forecasts.
Breakdown of ratings
Price targets: published for companies listed in the United States only.
Track record against expectations: reported EPS above consensus 9 times over the last 12 releases.
Source: ratings and forecasts published by analysts, collected on 07/11/2026. An analyst rating or target is not a guarantee.
Who owns the stock
Free float, institutional investors, large funds, executives and elected officials: declared positions in aTyr Pharma, Inc.
Sources: 13F filings (quarter shown), executives' Form 4 filings and US Congress members' disclosures, collected on 01/11/2026. Detailed disclosure obligations mainly apply to companies listed in the United States.
PEA and practical information
Rule applied: the French PEA accepts shares of companies headquartered in the European Union or the European Economic Area and subject to corporate income tax; ADRs and tax-exempt property companies (SIIC) are excluded. The institution holding the PEA confirms eligibility.
Frequently asked questions about aTyr Pharma, Inc.
What is the aTyr Pharma, Inc. share price?
Latest recorded price: 6.35 USD on 06/11/2026, for a market cap of 15.6 m USD.
What is the revenue of aTyr Pharma, Inc.?
190,000 USD for fiscal year 2025, with net income of -74.1 m USD (net margin -39,009.5 %).
What do analysts say about aTyr Pharma, Inc.?
Out of 10 analysts: 3 buy or strong buy, 7 hold, 0 sell or strong sell.
Is aTyr Pharma, Inc. stock eligible for the French PEA?
No: the company is headquartered outside the European Union and the European Economic Area (ISIN US0021202025).
How many employees does aTyr Pharma, Inc. have?
56 full-time employees according to the latest published profile.
Who runs aTyr Pharma, Inc.?
Sanjay S. Shukla is the company's chief executive.